Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its gene therapy
https://seekingalpha.com/news/4471542-sarepta-drops-as-report-suggests-fda-needs-new-trials-for-elevidys
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.